Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.

Molecular Therapy : the Journal of the American Society of Gene Therapy
Maria Caterina RotirotiSarah Tettamanti

Abstract

The successful implementation of chimeric antigen receptor (CAR)-T cell therapy in the clinical context of B cell malignancies has paved the way for further development in the more critical setting of acute myeloid leukemia (AML). Among the potentially targetable AML antigens, CD33 is insofar one of the main validated molecules. Here, we describe the feasibility of engineering cytokine-induced killer (CIK) cells with a CD33.CAR by using the latest optimized version of the non-viral Sleeping Beauty (SB) transposon system "SB100X-pT4." This offers the advantage of improving CAR expression on CIK cells, while reducing the amount of DNA transposase as compared to the previously employed "SB11-pT" version. SB-modified CD33.CAR-CIK cells exhibited significant antileukemic activity in vitro and in vivo in patient-derived AML xenograft models, reducing AML development when administered as an "early treatment" and delaying AML progression in mice with established disease. Notably, by exploiting an already optimized xenograft chemotherapy model that mimics human induction therapy in mice, we demonstrated for the first time that CD33.CAR-CIK cells are also effective toward chemotherapy resistant/residual AML cells, further supporting its ...Continue Reading

References

Jul 1, 1991·The Journal of Experimental Medicine·I G Schmidt-WolfI L Weissman
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·G GrossZ Eshhar
Jun 7, 2001·Proceedings of the National Academy of Sciences of the United States of America·S E FischerR H Plasterk
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Feb 9, 2007·Leukemia·V H J van der VeldenUNKNOWN European Study Group on MRD detection in ALL (ESG-MRD-ALL)
Jan 28, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Perry B HackettLaurence J N Cooper
Jan 30, 2010·Bioinformatics·Aaron R Quinlan, Ira M Hall
Apr 7, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Brian MoldtJacob Giehm Mikkelsen
Jan 31, 2012·Blood·Roland B WalterIrwin D Bernstein
Mar 6, 2012·Nature Methods·Ben Langmead, Steven L Salzberg
Jan 15, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Perry B HackettLaurence J N Cooper
Jul 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·David S RitchieH Miles Prince
Apr 12, 2014·PLoS Genetics·Johann de JongJeroen de Ridder
Sep 2, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Quan-Shun WangWei-Dong Han
Dec 7, 2014·Haematologica·Carol O'HearTerrence L Geiger
Jan 13, 2016·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andreas Gogol-DöringZoltán Ivics
Aug 3, 2016·The Journal of Clinical Investigation·Partow KebriaeiLaurence J N Cooper
Oct 13, 2016·Journal of Translational Medicine·José Eduardo VargasMartin H Bonamino
Dec 4, 2016·Nucleic Acids Research·Yongming WangZsuzsanna Izsvák
Feb 22, 2017·Journal of Hematology & Oncology·Hubert HacklRotraud Wieser
May 10, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Silvia ArcangeliLuca Varani
Jul 18, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Martino IntronaAlessandro Rambaldi
Jul 22, 2017·Frontiers in Immunology·Xingchun GaoWeilin Jin
Oct 2, 2017·Trends in Genetics : TIG·Partow KebriaeiZoltán Ivics
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Apr 15, 2018·Leukemia·Michael C Milone, Una O'Doherty
Nov 7, 2018·Cancer Immunology Research·Susanne H BaumeisterSarah Nikiforow

❮ Previous
Next ❯

Citations

Apr 29, 2021·EBioMedicine·Ella S AtsavapraneeMichael J Mitchell
May 28, 2021·Frontiers in Oncology·Alessandro IsidoriAntonio Curti
Jun 18, 2021·Stem Cell Research & Therapy·Gabrielle M RobbinsBranden S Moriarity
Jul 25, 2021·Leukemia·Sarah TettamantiMarta Serafini

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.